CHAMPIONS ONCOLOGY INC
For the period ended Apr 30, 2024. Filed Jul 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Jul 19, 2024
CSBR$4.84+1.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(Dollars in Thousands Except Share and Per Share Amounts)
| Year Ended April 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Oncology services revenue | $50,155 | $53,870 |
| Costs and operating expenses: | ||
| Cost of oncology services | 29,401 | 29,532 |
| Research and development | 9,544 | 11,545 |
| Sales and marketing | 7,064 | 7,002 |
| General and administrative | 11,067 | 10,240 |
| Loss on disposal of equipment | 435 | — |
| Asset impairment | — | 807 |
| Total costs and operating expenses | 57,511 | 59,126 |
| Loss from operations | (7,356) | (5,256) |
| Other income (expense): | ||
| Other income (expense), net | 48 | (11) |
| Loss before income tax expense | (7,308) | (5,267) |
| (Benefit) provision for income tax | (32) | 68 |
| Net loss | $(7,276) | $(5,335) |
| Net loss per common share outstanding | ||
| basic and diluted | $(0.54) | $(0.39) |
| Weighted average common shares outstanding | ||
| basic and diluted | 13,547,604 | 13,541,559 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.